Publications by authors named "Kemi Olugemo"
Article Synopsis
- Hereditary transthyretin amyloidosis (hATTR/ATTRv) is caused by the buildup of misfolded transthyretin protein, affecting peripheral nerves, and inotersen has shown promise in treating the associated polyneuropathy, according to the NEURO-TTR study results.
- The study included patients from Europe and North America who participated in a long-term open-label extension study, focusing on various efficacy measures like the modified Neuropathy Impairment Score and quality of life assessments while also monitoring safety.
- Results indicated that a significant proportion of patients improved or maintained their neurological function over time, with 39 patients who initially received a placebo showing notable progress
Article Synopsis
- The COVID-19 pandemic has raised concerns for patients with chronic diseases, particularly those with preexisting conditions that may worsen COVID-19 outcomes, like ATTR amyloidosis.
- ATTR amyloidosis leads to the buildup of amyloid fibrils in various organs, causing issues like heart problems and nerve damage, making patients with this condition especially vulnerable to complications during COVID-19.
- There is a need for further research on the risk and management of COVID-19 in ATTR amyloidosis patients, as they may require special care due to their increased risk of severe outcomes.
Introduction: Indomethacin is a potent analgesic that, similar to other nonsteroidal anti-inflammatory drugs, is associated with serious dose-related adverse events. There is a need for newer nonsteroidal anti-inflammatory drug products with improved tolerability. Low-dose submicron indomethacin was developed using SoluMatrix Fine Particle Technology™ to enable treatment at lower doses than commercially available indomethacin drug products.
View Article and Find Full Text PDFPurpose: This study compared the pharmacokinetic properties and safety profile of low-dose (18- and 35-mg) diclofenac capsules manufactured using SoluMatrix Fine Particle Technology (Trademark of iCeutica Inc. (Philadelphia, Pennsylvania), and the technology is licensed to Iroko Pharmaceuticals, LLC (Philadelphia, Pennsylvania) for exclusive use in NSAIDs), which produces submicron-sized drug particles with enhanced dissolution properties, to those of diclofenac potassium immediate-release (IR) 50-mg tablets.
Methods: This Phase 1, single-center, randomized, open-label, single-dose crossover study was conducted in 40 healthy volunteers.